SCHEMBL731571

SCHEMBL731571

COc1cccc(-c2c[c]cc(-c3nnn[nH]3)n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.44
NR1H3 Q13133 1/20 0.44
DCUN1D1 Q96GG9 1/20 0.44
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
XDH P47989 1/20 0.41
PLK1 P53350 1/20 0.41
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
RAB9A P51151 2/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
DYRK1A Q13627 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
CYP19A1 P11511 1/20 0.39
AURKA O14965 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL733059 0.85 NPC1 (0.40) MAPTSMN1; SMN2XDHRAB9ALMNA
SCHEMBL703677 0.82 DCUN1D1 (0.54) NR1H2NR1H3DCUN1D1MAPTXDH
SCHEMBL732981 0.80 IDO1 (0.40) MAPTSMN1; SMN2RAB9ALMNANPSR1
SCHEMBL733019 0.79 MEN1 (0.39) NR1H2NR1H3DCUN1D1MAPTSMN1; SMN2
SCHEMBL731210 0.78 CTSS (0.41)
SCHEMBL13545640 0.75 CYP19A1 (0.57) MAPTSMN1; SMN2RAB9ACYP19A1NFKB1
SCHEMBL730434 0.75 FYN (0.50) MAPTSMN1; SMN2PLK1RAB9ATSHR
SCHEMBL730902 0.75 ALDH1A1 (0.34) NR1H2NR1H3DCUN1D1MAPTSMN1; SMN2
SCHEMBL731454 0.75 DYRK1A (0.47) MAPTSMN1; SMN2RAB9AADORA2AADORA1
SCHEMBL730958 0.72 RAB9A (0.33) MAPTSMN1; SMN2MKNK1MKNK2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 NR1H2 700/4885NR1H3 663/4885DCUN1D1 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.